Hepatocellular Carcinoma

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Cabozantinib prolonged survival in relapsed HCC across a range of AFP levels, but a larger treatment benefit was observed with higher baseline AFP.

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

By

Sustained response duration, as opposed to complete or partial response, may be a better predictor of overall survival in HCC following cTACE.

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

By

The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

By

Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

By

Previous studies have demonstrated tivantinib prolonged progression-free survival and overall survival in hepatocellular carcinoma.

Radioembolization Shows Similar OS, Improved Toxicity vs Sorafenib in Hepatocellular Carcinoma

Radioembolization Shows Similar OS, Improved Toxicity vs Sorafenib in Hepatocellular Carcinoma

By

Patients were enrolled regardless of portal vein thrombosis status and were unable to tolerate other curative therapies.

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

By

Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

By

Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.

SIRT Does Not Improve Overall Survival vs Sorafenib in Hepatocellular Carcinoma

SIRT Does Not Improve Overall Survival vs Sorafenib in Hepatocellular Carcinoma

By

Researchers randomly assigned 459 patients to receive SIRT with 90Y-loaded resin microspheres for 2 to 5 weeks or oral sorafenib 400 mg twice daily continuously.

Oranitib Plus cTACE Fails to Prolong Overall Survival in Hepatocellular Carcinoma

Oranitib Plus cTACE Fails to Prolong Overall Survival in Hepatocellular Carcinoma

By

A previous study demonstrated that TACE plus orantinib insignificantly prolonged progression-free survival, though it did not improve OS.

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

By

Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.

Individualized Radiotherapy Effective in Liver Cancer

Individualized Radiotherapy Effective in Liver Cancer

By

The 1-year control rate was 99%, the 2-year control rate was 95%, and the median time to progression was 9 months.

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

By

The combination of axitinib and TACE is safe and potentially efficacious for patients with inoperable hepatocellular carcinoma.

FDA Approves Regorafenib for Second-line in Hepatocellular Carcinoma

FDA Approves Regorafenib for Second-line in Hepatocellular Carcinoma

By

Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.

RETREAT Score Highly Predictive of HCC Recurrence Risk After Liver Transplantation

RETREAT Score Highly Predictive of HCC Recurrence Risk After Liver Transplantation

By

The Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score was highly predictive of hepatocellular carcinoma (HCC) recurrence risk.

Polycystic Kidney Disease Correlated With Risk of Cancer

Polycystic Kidney Disease Correlated With Risk of Cancer

By

Polycystic kidney disease (PKD) may increase one's risk of developing cancer of the liver, colon, and kidney.

Regorafenib Improves Survival in Unresectable Liver Cancer

Regorafenib Improves Survival in Unresectable Liver Cancer

By

The kinase inhibitor regorafenib conferred improved overall survival in patients with unresectable hepatocellular carcinoma (HCC).

Sartans May Improve Survival, Time to Recurrence in Liver Cancer

Sartans May Improve Survival, Time to Recurrence in Liver Cancer

For patients with hepatocellular carcinoma, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved survival.

Sorafenib Not Effective After Resection, Ablation for Hepatocellular Carcinoma

Sorafenib Not Effective After Resection, Ablation for Hepatocellular Carcinoma

By

Treatment with sorafenib is not effective in the adjuvant setting for hepatocellular carcinoma following resection or ablation.

Three Alcoholic Drinks Per Day Raises Liver Cancer Risk

Three Alcoholic Drinks Per Day Raises Liver Cancer Risk

People who have three or more alcoholic drinks per day could be raising their odds for liver cancer.

American Patients Living Longer After Cancer, But Disparities Remain

American Patients Living Longer After Cancer, But Disparities Remain

Survival rates are improving for many people with cancers of the breast, prostate, lung, liver, and colon or rectum.

Addition of Erlotinib to Sorafenib Does Not Improve Survival in Advanced Liver Cancer

Addition of Erlotinib to Sorafenib Does Not Improve Survival in Advanced Liver Cancer

Addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.

A New Approach to Assessing Liver Function in Hepatocellular Carcinoma

A New Approach to Assessing Liver Function in Hepatocellular Carcinoma

By

By analyzing data from international databases, researchers develop an alternative to the Child-Pugh system.

Safety, Efficacy of Sorafenib Treatment for Hepatocellular Carcinoma Among Age Groups

Safety, Efficacy of Sorafenib Treatment for Hepatocellular Carcinoma Among Age Groups

Safety and efficacy of sorafenib, the standard of care for advanced hepatocellular carcinoma, in older patients, evaluated.

Biomarker May Predict Response to Sorafenib in Patients with Liver Cancer

Biomarker May Predict Response to Sorafenib in Patients with Liver Cancer

Patients with liver cancer whose tumors cells have less differentiated mesenchymal phenotype and CD44 are less likely to respond to sorafenib.

Obesity Speeds Aging of Liver, Linked to Cancer

Obesity Speeds Aging of Liver, Linked to Cancer

Heavier people might be more prone to liver cancer, insulin problems.

NANETS: Radical Resection of Pancreatic Neuroendocrine Tumors with Liver Mets Often Prolongs Survival

NANETS: Radical Resection of Pancreatic Neuroendocrine Tumors with Liver Mets Often Prolongs Survival

By

Poorly differentiated pancreatic neuroendocrine carcinoma (PNEC) grade 3 tumors demonstrate lower survival after radical resection of PNETs.

For Hepatocellular Carcinoma, Protein May Trigger Cancer Cell Death

For Hepatocellular Carcinoma, Protein May Trigger Cancer Cell Death

Researchers have discovered that a protein called apoptosis inhibitor of macrophage (AIM) prevents tumor development in liver cells.

Sorafenib Plus Selective Internal Radiation Therapy (SIRT) Improves Survival for Patients with Liver Cancer

Sorafenib Plus Selective Internal Radiation Therapy (SIRT) Improves Survival for Patients with Liver Cancer

Patients with advanced hepatocellular carcinoma may benefit from combined therapy of sorafenib and selective internal radiation therapy.

Everolimus Didn't Improve Survival in Advanced HCC

Everolimus Didn't Improve Survival in Advanced HCC

Researchers found no survival difference found between patients receiving everolimus or placebo.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs